Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 8.31
-0.02 (-0.24%)
Apr 29, 2026, 1:57 PM CST
Merdury Biopharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | - | 4.96 | 1.03 | 2.68 | - | Upgrade
|
| Revenue Growth (YoY) | - | 380.44% | -61.46% | - | - | Upgrade
|
| Cost of Revenue | - | 0.78 | 0.44 | 1.51 | - | Upgrade
|
| Gross Profit | - | 4.18 | 0.59 | 1.17 | - | Upgrade
|
| Selling, General & Admin | 24.37 | 25.57 | 24.91 | 16.66 | 2.48 | Upgrade
|
| Research & Development | 44.18 | 32.66 | 21.37 | 15.41 | 2.82 | Upgrade
|
| Operating Expenses | 68.55 | 58.23 | 46.28 | 32.07 | 5.3 | Upgrade
|
| Operating Income | -68.55 | -54.04 | -45.69 | -30.9 | -5.3 | Upgrade
|
| Interest Expense | -0.9 | -0.8 | -0.71 | -0.4 | -0.01 | Upgrade
|
| Interest & Investment Income | 3.2 | 4.11 | 3.07 | 0.33 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.2 | 0.21 | - | -0.06 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.21 | - | -0.48 | -0.22 | - | Upgrade
|
| EBT Excluding Unusual Items | -66.65 | -50.53 | -43.82 | -31.25 | -5.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.62 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.1 | - | - | - | - | Upgrade
|
| Pretax Income | -67.17 | -50.53 | -43.82 | -31.25 | -5.31 | Upgrade
|
| Income Tax Expense | 0.06 | 0.04 | - | - | - | Upgrade
|
| Net Income | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 | Upgrade
|
| Net Income to Common | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 | Upgrade
|
| Shares Outstanding (Basic) | 419 | 416 | 398 | 376 | 277 | Upgrade
|
| Shares Outstanding (Diluted) | 419 | 416 | 398 | 376 | 277 | Upgrade
|
| Shares Change (YoY) | 0.70% | 4.43% | 5.83% | 36.09% | 165.94% | Upgrade
|
| EPS (Basic) | -0.16 | -0.12 | -0.11 | -0.08 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.16 | -0.12 | -0.11 | -0.08 | -0.02 | Upgrade
|
| Free Cash Flow | -57.72 | -44.73 | -55.07 | -94.35 | -11.77 | Upgrade
|
| Free Cash Flow Per Share | -0.14 | -0.11 | -0.14 | -0.25 | -0.04 | Upgrade
|
| Gross Margin | - | 84.30% | 57.31% | 43.73% | - | Upgrade
|
| Operating Margin | - | -1088.90% | -4423.04% | -1152.91% | - | Upgrade
|
| Profit Margin | - | -1018.90% | -4241.63% | -1166.05% | - | Upgrade
|
| Free Cash Flow Margin | - | -901.17% | -5331.17% | -3520.60% | - | Upgrade
|
| EBITDA | -59.67 | -48.15 | -41.62 | -29.15 | -4.73 | Upgrade
|
| D&A For EBITDA | 8.87 | 5.9 | 4.07 | 1.75 | 0.57 | Upgrade
|
| EBIT | -68.55 | -54.04 | -45.69 | -30.9 | -5.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.